|Dr. Aoife M. Brennan M.D., MB, BCh, BAO, MMSc||Pres, CEO & Director||737.3k||N/A||1976|
|Dr. Richard J. Riese M.D., Ph.D.||Chief Medical Officer||209.16k||N/A||1963|
|Dr. Timothy K. Lu||Co-Founder||N/A||N/A||N/A|
|Dr. James J. Collins||Co-Founder||N/A||N/A||1967|
|Mr. Gregg D. Beloff||Interim Chief Financial Officer||N/A||N/A||1968|
|Mr. Antoine Awad||Chief Operating Officer||N/A||N/A||N/A|
|Dr. David L. Hava||Chief Scientific Officer||N/A||N/A||1975|
|Dr. Elizabeth Wolffe||Head of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Mr. Daniel Rosan||Sr. VP, Head of Fin. & Investor Relations||N/A||N/A||N/A|
|Mr. Adam Thomas||Chief People Officer & Sec.||N/A||N/A||N/A|
Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase II clinical trial to treat phenylketonuria (PKU), as well as pre-clinical stage product SYNB1934 for the treatment of PKU; and SYNB8802 that is in Phase I clinical trial for the treatment of Enteric Hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Synlogic, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.